Synchron Raises US$200 Million in Series D Financing
Synchron has secured US$200 million in a Series D funding round aimed at accelerating the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform. The investment will also support development of a “next-generation, transcatheter, high-channel whole-brain interface.”
Funding Objectives and Development Plans
The capital will drive pivotal trials forward and prepare for the commercial launch of the Stentrode BCI system. Synchron plans to expand its team by hiring engineers, neuroscientists, and operators to enhance the next generation of BCI technology.
Investor Participation
The financing round was led by Double Point Ventures, with continued support from existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New investors joining the round include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Funding Summary
This latest funding raises Synchron’s total capital to US$345 million, according to the company’s recent statement.
“Bolstered by this Series D funding, Synchron will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs.”
Author’s summary: Synchron’s substantial Series D investment will fast-track the launch and development of advanced brain-computer interfaces, with new hires and expanded trials positioning the company for growth.